657 related articles for article (PubMed ID: 37857607)
1. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B; Jenkins MR; Best SA; Freytag S; Prasad K; Holst J; Endersby R; Johns TG
Signal Transduct Target Ther; 2023 Oct; 8(1):400. PubMed ID: 37857607
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma targeted therapy: updated approaches from recent biological insights.
Touat M; Idbaih A; Sanson M; Ligon KL
Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
[TBL] [Abstract][Full Text] [Related]
3. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of Treatment Resistance in Glioblastoma.
Ou A; Yung WKA; Majd N
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396284
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the Landscape of Pediatric Glioblastoma Biomarkers: A Comprehensive Review of Enhancing Diagnostics and Therapeutic Insights.
Katole VR; Kaple M
Cureus; 2024 Mar; 16(3):e57272. PubMed ID: 38686271
[TBL] [Abstract][Full Text] [Related]
6. Omics sciences and precision medicine in glioblastoma.
Micheletti C; Bonetti G; Madeo G; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Manganotti P; Caruso P; Bernini A; Fulcheri E; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):77-84. PubMed ID: 37994751
[TBL] [Abstract][Full Text] [Related]
7. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
8. Deregulated signalling networks in human brain tumours.
Grzmil M; Hemmings BA
Biochim Biophys Acta; 2010 Mar; 1804(3):476-83. PubMed ID: 19879382
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma precision therapy: From the bench to the clinic.
Zhou Y; Wu W; Bi H; Yang D; Zhang C
Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
11. Characterization of molecular pathways for targeting therapy in glioblastoma.
Wagle N; Nguyen M; Carrillo J; Truong J; Dobrawa L; Kesari S
Chin Clin Oncol; 2020 Dec; 9(6):77. PubMed ID: 33353366
[TBL] [Abstract][Full Text] [Related]
12. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
13. New hints towards a precision medicine strategy for IDH wild-type glioblastoma.
White K; Connor K; Clerkin J; Murphy BM; Salvucci M; O'Farrell AC; Rehm M; O'Brien D; Prehn JHM; Niclou SP; Lamfers MLM; Verreault M; Idbaih A; Verhaak R; Golebiewska A; Byrne AT
Ann Oncol; 2020 Dec; 31(12):1679-1692. PubMed ID: 32918998
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies for the Treatment of Glioblastoma in Adults.
Chuang DF; Lin X
Curr Oncol Rep; 2019 May; 21(7):61. PubMed ID: 31102038
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets in glioblastoma.
Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
[TBL] [Abstract][Full Text] [Related]
16. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
[TBL] [Abstract][Full Text] [Related]
17. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic pathways and glioblastoma treatment: insights from signaling cascades.
Allen BK; Stathias V; Maloof ME; Vidovic D; Winterbottom EF; Capobianco AJ; Clarke J; Schurer S; Robbins DJ; Ayad NG
J Cell Biochem; 2015 Mar; 116(3):351-63. PubMed ID: 25290986
[TBL] [Abstract][Full Text] [Related]
19. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.
Wallace GC; Dixon-Mah YN; Vandergrift WA; Ray SK; Haar CP; Mittendorf AM; Patel SJ; Banik NL; Giglio P; Das A
Metab Brain Dis; 2013 Sep; 28(3):355-66. PubMed ID: 23543207
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
